					ATTY DOCKET NO.		APPLICATION	NO.	
·					11352-004-999 10/726,824				
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT					
	18	(Use several sheets if no	ecessary)		George ZABREC	CKY_		<del></del> -	
					FILING DATE GROUP 1655			•	
	M	AY 1 4 2004 5			December 3, 200	3	1614 6	54	
U.S. PATENT DOCUMENTS									
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME CLASS		CLASS	SUBCLASS FILING DATE SUBCLASS IF APPROPRIATE		
			·						
	ļ					<u> </u>			
						<u> </u>	<u></u>		
			FOREIGN	PATENT DOC	UMENTS				
		DOCUMENT NUMBER	DATE	co	UNTRY	CLASS	SUBCLASS	TRANSL	ATION
		1		1		T	1	YES	NO
								<u> </u>	
·						J	L	ļ	
		OTHER REFERE	NCES (Incli	uding Author, Tit	le, Date, Pertinent	Pages, I	Etc.)		
(2)	C01	Abe Y. et al. Effectiveness 1994; 52(7):1817-22 (in Ja	panese with Eng	glish abstract)					linsho.
	C02	Arase Y. et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997; 79(8):1494-500							
	C03	Barbaro G. et al Hepatic glutathione deficiency in chronic hepatitis C: quantitative evaluation in patients who are HIV positive and HIV negative and correlations with plasmatic and lymphocytic concentrations and with the activity of the liver disease. Am J Gastroenterol. 1996; 91(12):2569-73							
	C04	Berkson B.M. A conservative triple antioxidant approach to the treatment of hepatitis C. Combination of alpha lipoic acid (thioctic acid), silymarin, and selenium: three case histories. <i>Med Klin</i> . 1999; 94 Suppl 3:84-9							
	C05	Boigk G. et al. Silymarin duct obliteration in rats. Ho	retards collage	en accumulation in			is secondary	to comple	te bile
	C06	Boya P. et al. Antioxidant	status and gluta	athione metabolism i	n peripheral blood mor	nonuclear o	ells from pati	ents with	
	C07	Bustamante J. et al., Alpha-	chronic hepatitis C. J Hepatol. 1999; 31(5):808-14  Bustamante J. et al., Alpha-lipoic acid in liver metabolism and disease. Free Radic Biol Med . 1998; 24(6):1023-39						
	C08	Buzzelli G. et al. A pilot si				noline com	plex (1dB101	6) in chro	nic
	C09		active hepatitis. Int J Clin Pharmacol Ther Toxicol. 1993; 31:456-460  Chrobot A.M. et al. Antioxidant defense in children with chronic viral hepatitis B and C. Med Sci Monit 2000; 6(4): 713-8						
	C10	Cook G.C. et al. Results of	f a controlled cl	linical trial of glutath	nione in cases of hepatic	c cirrhosis.	Gut 1965; 6(	5):472-6	
	CH	Dehmlow C. et al. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 1996; 23:749-754							
	C12	Eberhardt G. et al. Controlled study of the therapeutic effect of B vitamins and an anabolic steroid in chronic hepatitis. Disch Med Wochenschr. 1975; 100(41):2074-82 (in German with English abstract)							
	C13	Feher I. et al. Liver-protec Hungarian with English abstr	ract)						
	C14	Ferenci P. et al., Randomize 9:105-113	ed controlled tri	al of silymarin treatm	ent in patients with cirr	hosis of th	e liveт. <i>J Неро</i>	atol. 1989;	
	C15	Fujisawa Y. et al. Glycyrrl effect on liver cells in viral				echanism	of its anti-infl	ammatory	
	C16	Gagliardi B. et al., Results out at two medical centers.	of a double bli	nd study on the effec		eatment of	cute viral hep	atitis, carr	ied
	C17	Gut J. et al. Mechanisms o			Pharmacol Ther. 1993	; 58(2): 13	3-55		
	C18	Hargreaves R.J. et al. Stud assessment in mice of the p 64(3):380-92							
	C19	Hill D.B. et al. Antioxidan	ts attenuate nuc	lear factor-kappa B	activation and tumor ne	crosis fact	or-alpha prod	uction in	
		<del></del>							

Examiner C. K. Tate Date Considered 6/29/05

		Sheet 2 of 3
(D)	T	alcoholic hepatitis patient monocytes and rat Kupffer cells, in vitro. Clin Biochem. 1999; 32(7):563-70
	C20	Houglum K. et al. A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology 1997; 113(4): 1069-73
-	C21	Hruby K. et al. Chemotherapy of Amanita phalloides poisoning with intravenous silibinin. Hum Toxicol. 1983; 2:183-195
	C22	limuro Y. et al. The glutathione precursor L-2-oxothiazolidine-4-carboxylic acid protects against liver injury due to chronic enteral ethanol exposure in the rat. Hepatology 2000; 31(2): 391-8
	C23	lino S. et al. Therapeutic effects of stronger neo-minophagen C at different doses on chronic hepatitis and liver cirrhosis.  Hepatol Res. 2001; 19(1): 31-40
	C24	Kang S.Y. et al. Hepatoprotective activity of scopoletin, a constituent of Solarium lyratum. Arch Pharm Res. 1998; 21(6): 718-22
	C25	Khodykin A.V. The efficacy of a diet enriched by lipotropic factors, and vitamin C and vitamin B-complex in patients with chronic hepatitis. <i>Vopr Pitan</i> . 1958; 17(2):19-29 (in Russian with English summary)
	C26	Komar VI. Application of vitamin B12 in combined treatment of viral hepatitis. Vopr Pitan. 1982; (1):26-9 (in Russian with English summary)
	C27	Li X.J., Scavenging effects on active oxygen radicals by schizandrins with different structures and configurations. Free
	C28	Radic Biol Med. 1990; 9(2):99-104  Liu G.T. Pharmacological actions and clinical use of fructus schizandrae. Chin Med J. (Engl) 1989;102(10):740-9
·	C29	Liu K.T., Pharmacological properties of Dibenzo[a,c]cyclooctene derivatives isolated from Fructus Schisandra Chinensis III. Inhibitory effects on carbon tetrachloride-induced lipid peroxidation, metabolism and covalent binding of carbon tetrachloride to lipids. Chem Biol Interact. 1982; 41(1):39-47
	C30	Liu S.L. et al. Vitamin E therapy of acute CCl4-induced hepatic injury in mice is associated with inhibition of nuclear factor kappa B binding. Hepatology 1995; 22(5):1474-81
	C31	Loguercio C. et al. Alpha-glutathione transferases in HCV-related chronic hepatitis: a new predictive index of response to interferon therapy? J Hepatol. 1998; 28(3):390-5
	C32	Look M.P. et al. Interferon/antioxidant combination therapy for chronic hepatitis C - a controlled pilot trial. Antiviral Res. 1999; 43(2):113-22
	C33	Lu H. et al., Effect of dibenzo[a,c]cyclooctene lignans isolated from Fructus schizandrae on lipid peroxidation and anti- oxidative enzyme activity. Chem Biol Interact. 1991; 78(1):77-84
	C34	Luper S. A review of plants used in the treatment of liver disease: Part 1. Altern Med Rev. 1998; 3:410-421
	C35	Magliulo E. et al. Results of a double blind study on the effect of silymarin in the treatment of acute viral hepatitis, carried out at two medical centres. Med Klin. 1978 Jul 14; 73(28-29): 1060-5 (in German with English summary)
	C36	Mahmood S. et al. Effect of vitamin E on serum aminotransferase and thioredoxin levels in patients with viral hepatitis C. Free Radic Res. 2003; 37(7):781-5
	C37	Marshall A.W. et al. Treatment of alcohol-related liver disease with thioctic acid: a six month randomized double-blind trial. Gut 1982; 23(12):1088-93
	C38	Matsuo K. et al. Lamivudine and glycyrrhizin for treatment of chemotherapy-induced hepatitis B virus (HBV) hepatitis in a chronic HBV carrier with non-Hodgkin lymphoma. Leuk Lymphoma 2001; 41(1-2): 191-5
	C39	McPartland J.M. Viral hepatitis treated with Phyllanthus amarus and milk thistle (Silybum marianum). Complementary Medicine International 1996; March/April: 40-42
	C40	Meydani S.N. et al. Vitamin E supplementation and in vivo immune response in healthy elderly subjects. A randomized controlled trial. JAMA 1997; 277(17): 1380-6
	C41	Mitra A. et al. Effect of ascorbic acid esters on hepatic glutathione levels in mice treated with a hepatotoxic dose of acetaminophen. J Biochem Toxicol. 1991; 6(2):93-100
	C42	Moller E. et al. A contribution to the treatment of chronic liver diseases Med Klin. 1976; 71(43):1831-5
	C43	Morazzoni P. et al., Comparative pharmacokinetics of silipide and silymarin in rats. Eur J Drug Metab Pharmacokinet. 1993; 18:289-297
	C44	Moscarella S. et al., Therapeutic and antilipoperoxidant effects of silybin-phosphatidylcholine complex in chronic liver disease: preliminary results. Curr Ther Res. 1993; 53:98-102
	C45	Nagita A. et al. Assessment of hepatic vitamin E status in adult patients with liver disease. Hepatology 1997; 26(2):392-7
	C46	Nakashima T. et al. Thioredoxin levels in the sera of untreated viral hepatitis patients and those treated with glycyrrhizin or ursodeoxycholic acid. Antioxid Redox Signal. 2000 Winter; 2(4):687-94
	C47	Numazaki K. et al. Effect of glycyrrhizin in children with liver dysfunction associated with cytomegalovirus infection.  Tohoku J Exp Med. 1994; 172(2):147-53
_	C48	Okamoto T. The protective effect of glycyrrhizin on anti-Fas antibody-induced hepatitis in mice. Eur J Pharmacol. 2000; 387(2): 229-32.
	C49	Okamoto T. et al Glycyrrhizin protects mice from concanavalin A-induced hepatitis without affecting cytokine expression. Int J Mol Med. 1999; 4(2):149-52
	C50	Patrick L. Hepatitis C: epidemiology and review of complementary/alternative medicine treatments. Altern Med Rev. 1999; 4(4):220-38
	C51	Pauling L. Vitamin C prophylaxis for posttransfusion hepatitis. Am J Clin Nutr. 1981; 34(9):1978-80
	C52	Rambousek V. et al. Severe Amanita phalloides poisoning in a 7-year-old girl. Cesk Pediatr. 1993; 48:332-333 (in Czech with English summary)
6	C53	Ravindranath V. et al. Effect of modulators of glutathione synthesis on the hepatotoxicity of 2-methylfuran. Biochem Pharmacol 1991; 41(9): 1311-8
101	C54	Rocchi E. et al. Antioxidant liposoluble vitamins and carotenoids in chronic hepatitis. 2001; 12(2):116-121

Examine C. R. Tate Date Considered 6/28/05

		Sheet 3 Of 3
(D)	C55	Sabeel A.I. et al. Intensive hemodialysis and hemoperfusion treatment of Amanita mushroom poisoning. Mycopathologia 1995; 131:107-114
1	C56	Salmi H.A. et al. Effect of silymarin on chemical, functional, and morphological alterations of the liver; A double blind controlled study. Scand J Gastroenterol. 1982; 17:517-521
	C57	Schalm S.W. et al. New treatment strategies in non-responder patients with chronic hepatitis C. J Hepatol. 1999; 31 Suppl 1:184-8
	C58	Shibata S. A drug over the millennia: pharmacognosy, chemistry, and pharmacology of licorice. Yakugaku Zasshi 2000; 120(10): 849-62
	C59	Sinclair S. Chinese herbs: a clinical review of Astragalus, Ligusticum, and Schizandrae. Altern Med Rev. 1998; 3(5): 338-44
	C60	Speck R.F. et al. Prednisolone stimulates hepatic glutathione synthesis in mice. Protection by prednisolone against acetaminophen hepatotoxicity in vivo. J Hepatol. 1993; 18(1): 62-7
	C61	Sun F. et al. Evaluation of oxidative stress based on lipid hydroperoxide, vitamin C and vitamin E during apoptosis and necrosis caused by thioacetamide in rat liver. Biochim Biophys Acta. 2000;1500(2):181-5
	C62	Sun F. et al. Evaluation of oxidative stress during apoptosis and necrosis caused by carbon tetrachloride in rat liver. Biochim Biophys Acta. 2001;1535(2):186-91
	C63	Swietek K. et al. Reduced glutathione concentration in erythrocytes of patients with acute and chronic viral hepatitis. J Viral Hepatol. 1997; 4:139-41
	C64	Takyar S.S. et al. Vitamin B12 stalls the 80 S ribosomal complex on the hepatitis C internal ribosome entry site. J Mol Biol. 2002; 319(1):1-8
	C65	Tandon A. et al. Treatment of subacute hepatitis with Lamivudine and intravenous Glycyrrhizin: a pilot study. Hepatol Res. 2001; 20(1): 1-8
	C66	Tanyalcin T. et al. The effects of chronic hepatitis C and B virus infections on liver reduced and oxidized glutathione concentrations. Hepatol Res. 2000; 18(2):104-109
	C67	Tsubota A. et al. Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients. Eur J Gastroenterol Hepatol. 1999; 11(10):1077-83
	C68	Valenzuela A. et al. Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin. Biol Res. 1994; 27(2):105-12
	C69	Vailati A. et al. Randomized open study of the dose-effect relationship of a short course of IdB 1016 in patients with viral or alcoholic hepatitis. Fitoterapia 1993; 64:219-228
	C70	van Rossum T.G. et al. Pharmacokinetics of intravenous glycyrrhizin after single and multiple doses in patients with chronic hepatitis C infection. Clin Ther. 1999; 21(12):2080-90
	C71	van Rossum T.G. et al. Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial. J Gastroenterol Hepatol. 1999; 14(11):1093-1099
	C72	van Rossum T.G. et al. Review article: glycyπhizin as a potential treatment for chronic hepatitis C. Aliment Pharmacol Ther. 1998; 12(3):199-205
	C73	Vendermiale G. et al. Oxidative stress in symptom-free HCV carriers: relation with ALT flare-up. Eur J Clin Invest. 2001; 31(1):54-63
	C74	Vogel G. et al. Protection by silibinin against Amanita phalloides intoxication in beagles. Toxicol Appl Pharmacol. 1984; 73:355-362
	C75	von Herbay A. et al. Vitamin E improves the aminotransferase status of patients suffering from viral hepatitis C: a randomized, double-blind, placebo-controlled study. Free Radic Res. 1997; 27(6):599-605
	C76	von Herbay A. et al. Diminished plasma levels of vitamin E in patients with severe viral hepatitis. Free Radic Res. 1996, 25(6):461-6
	C77	Yamashiki M. et al. Effects of the Japanese herbal medicine "Sho-saiko-to" (TJ-9) on in vitro interleukin-10 production by peripheral blood mononuclear cells of patients with chronic hepatitis C. Hepatology 1997; 25(6):1390-7
	C78	Yoshikawa M. et al. Mechanisms of Hepatocellular Injury: Effects of Glycyrrhizin on Immune-Mediated Cytotoxicity. J Gastroenterol Hepatol. 1997; 12(3):243-248
9)	C79	Younes M. et al. Protection by exogenous glutathione against hypoxic and cyanide-induced damage to isolated perfused rat livers. Toxicol Lett. 1990; 50(2-3):229-36
		·

EXAMINER C. R. Tate	DATE CONSIDERED	6/29/05
---------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.